Zacks.com on MSN5d
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...
The Pharma Letter6d
Patritumab deruxtecan closer to market
The HERTHENA-Lung02 Phase III trial of patritumab deruxtecan in advanced EGFR-mutated NSCLC patients who received prior EGFR ...
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial
In the trial, most interstitial lung disease events were observed to be low grade, with two grade 5 ILD events being reported ...
The American Journal of Managed Care2h
Advances in ADCs: Opportunities for Treatment, Challenges, and Managing Toxicities
Multiple sessions at ESMO Congress 2024 covered antibody-drug conjugates (ADCs), which are an emerging therapy that holds ...
pharmaphorum6d
After FDA no, MSD/Daiichi post new data with lung cancer ADC
The result is a welcome endorsement of patritumab derxutecan's potential after the HER3-directed antibody-drug conjugate (ADC ...
PMLiVE4d
Merck/Daiichi Sankyo’s ADC candidate shows promise in phase 3 lung cancer trial
Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab ...
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.